Navigation Links
PAREXEL International Reports First Quarter Fiscal Year 2014 Results
Date:10/29/2013

BOSTON, Oct. 29, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the first quarter Fiscal Year 2014, which ended on September 30, 2013. 

In commenting on the results of the quarter, Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer, stated, "In the first quarter, we drove continued improvement in our productivity and efficiency initiatives, while at the same time keeping a close eye on costs and proactively investing in the future on a targeted basis.  This resulted in sequential and year-over-year improvements in gross margins across all three of our business segments, and significant improvement in operating margin.  We achieved these results with a slightly lower than expected level of revenue caused by contract signature delays in the quarter, and typical seasonality patterns."

Mr. von Rickenbach continued, "New business in the quarter was less than anticipated due to lower new business flow from some strategic partners, delayed client decisions with regard to some of our pending proposals, and a win rate that was lower than expected.  Nevertheless, our outlook for new business remains very positive.  We entered the second quarter with a high level of pending proposals, and have had a good start with respect to wins thus far in the month of October.  Our long-term book-to-bill target of 1.2 remains unchanged.  The current strength of the market for our products and services and our favorable competitive position support this."

"I am excited about the opportunities that are in front of us as one of the world's leading biopharmaceutical services companies.  Outsourcing penetration rates have ticked up, we are capturing share from smaller competitors, and there is healthy fund flow into small and emerging biopharmaceutical companies
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Biotech Services Take Advantage of Technological Revolution through Innovations - Research Report on Life Technologies, PerkinElmer, PAREXEL, Genomic Health, and Bio-Reference
2. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
3. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
4. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
5. PAREXEL International to Present at Morningstar Conference
6. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
7. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
8. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
9. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
10. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
11. PAREXEL International to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... hosting a webinar to provide advanced scientific research into new classes of Nanoscale ... and energy. Touted as 'the wonder material of the 21st Century' by ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... 25, 2012 Covance Inc. (NYSE: CVD ... ended December 31, 2011 of $0.35 per diluted share. ... diluted share in charges, approximately $0.10 of which relates ... $0.11 of which relates to the termination of a ...
... HANOVER, N.J., Jan. 25, 2012 Novartis Pharmaceuticals Corporation (NPC) ... and the Class, today announced an agreement to resolve the ... in the US District Court for the Southern District of ... the ongoing proceedings and provide a payment of up to ...
... PARK, Calif., Jan. 24, 2012 SRI International has ... the time required for researchers to construct genome-scale models ... of metabolic and physical processes that determine the physiological ... used to predict cell growth rate, combinations of chemicals ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research 2
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... electronics for next-generation biomedical devices has prompted the ... at Cornell, funded by the National Science Foundation ... million over five years from NSF,s Integrative Graduate ... fellows will work in teams to design and ...
... It all started with flowers: in the nineties of ... of a particular gene in petunias inhibited its activity ... few years later it was found that the mechanism ... the cells. Finally, in the late nineties the Nobel ...
... news for public health: Bioengineering researchers from the EPFL ... that can deliver vaccines more effectively, with fewer side ... current vaccine technologies. Described in an article ... the vaccine delivery platform is a deceptively simple combination ...
Cached Biology News:IGERT fellows to design biodevices using flexible electronics 2Mechanism for the in-vivo transport of siRNA 2Mechanism for the in-vivo transport of siRNA 3New nanoparticle vaccine is more effective but less expensive 2New nanoparticle vaccine is more effective but less expensive 3
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: